Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma.

Journal of hepatology - 1 Jan 2007

Lin Shi-Ming, Yu Ming-Lung, Lee Chuan-Mo, Chien Rong-Nan, Sheen I-Shyan, Chu Chia-Ming, Liaw Yun-Fan

Abstract excerpt

BACKGROUND/AIMS: The long-term outcomes of interferon-alpha (IFN-alpha) therapy in hepatitis B e antigen (HBeAg) seropositive patients remain controversial. This study was conducted to address this issue. METHODS: The long-term outcomes were compared in 233 IFN-treated patients and 233 well-matched untreated controls. RESULTS: The cumulative incidence at the end of 15 years of follow-up (median 6.8 years, range...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to Carcinoma, Hepatocellular

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Hepacivirus

Share to Hepatitis B, Chronic

Share to Hepatitis B e Antigens

Share to Interferon Type I

Share to Liver Cirrhosis

Share to Liver Neoplasms

Source

Identifiers

PMID: 17107734
DOI: 10.1016/j.jhep.2006.08.021

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma.PMID 17107734Read ↗

Short- and long-term outcome of interferon therapy for chronic hepatitis B infection.Semantic proximity Read ↗

Long-term efficacy of interferon therapy in patients with chronic hepatitis B virus infection in Japan.Semantic proximity Read ↗

Interferon Therapy of Chronic Hepatitis BSemantic proximity Read ↗

Efficacy of long-term interferon therapy in chronic hepatitis B patients with HBV genotype C.Semantic proximity Read ↗

Risk of hepatocellular carcinoma development in cases of hepatitis C treated by long-term, low-dose PEG-IFNα-2a.Semantic proximity Read ↗

[Interferon in hepatitis B].Semantic proximity Read ↗

Risk factors and the effect of interferon therapy in the development of hepatocellular carcinoma: a multivariate analysis in 343 patients.Semantic proximity Read ↗

Liver Fibrosis and Body Mass Index Predict Hepatocarcinogenesis following Eradication of Hepatitis C Virus RNA by Direct-Acting Antivirals.Semantic proximity Read ↗

Long-term follow-up of Japanese patients with chronic hepatitis B treated with interferon-alpha.Semantic proximity Read ↗

Influence of viral load and genotype in the progression of Hepatitis B-associated liver cirrhosis to hepatocellular carcinoma.Semantic proximity Read ↗

Potential capacity of interferon-α to eliminate covalently closed circular DNA (cccDNA) in hepatocytes infected with hepatitis B virusSemantic proximity Read ↗

Liver Gene Expression Profiles Correlate with Virus Infection and Response to Interferon Therapy in Chronic Hepatitis B PatientsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.